Get in touch
555-555-5555
mymail@mailservice.com
PBS Changes for 1 July 2021
Practice Managers Australia • Jul 09, 2021
PBS Changes from 1 July 2021
Please find below information relating to new and amended Pharmaceutical Benefits Scheme (PBS) listings from 1 July 2021. This information relates to the administration of these listings by Services Australia. For further information on broader PBS changes, please visit the PBS website. Relevant information and authority application forms have been updated and can be accessed through Services Australia website.
Dupilumab for Severe Asthma
A grandfather listing was implemented for Dupilumab 200mg/1.14ml syringe.
Guselkumab for Psoriatic arthritis
Guselkumab is now PBS listed for Psoriatic Arthritis as Authority Required (Written). Authority requests must be submitted in-writing only via mail or electronic upload through HPOS form upload function.
Infliximab subcutaneous formulation is now PBS listed for Rheumatoid arthritis, Crohn’s disease and Ulcerative colitis.
Tofacitinib for Ulcerative colitis
Tofacitinib is now PBS listed for moderate to severe Ulcerative Colitis.
Sapropterin for maternal hyperphenylalaninaemia due to phenylketonuria
Sapropterin is now PBS listed for maternal hyperphenylalaninaemia due to phenylketonuria as Authority Required (Telephone / electronic listing). Authority approval request can be made in real time using the Online PBS Authorities system (see www.servicesaustralia.gov.au/HPOS).
To learn more about these updates, please contact Services Australia directly.
At Practice Managers Australia, we support Practice Managers in both staff recruitment and retention, and ensure that our service and advice is tailored to your specific goals to promote growth and flourishing.
OUR PARTNERS
